Pharmacogenetics of colorectal cancer.
作者： Sharon Marsh
DOI: 10.1517/14656566.6.15.2607
关键词: Oxaliplatin 、 Irinotecan 、 Chemotherapy combinations 、 Cancer 、 Internal medicine 、 Colorectal cancer 、 Pharmacogenetics 、 Oncology 、 Medicine 、 Chemotherapy 、 Toxicity
摘要: Colorectal cancer is one of the most common types in both men and women. Multiple chemotherapy combinations exist; however, there currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms genes involved metabolism, transport or targets commonly used drugs (5-fluorouracil, irinotecan oxaliplatin) have been described. Many require validation large prospective trials before they can be as markers outcome and/or toxicity. This review describes data available on key that are associated with toxicity response colorectal cancer.
informapharmascience.com参考文章(75)
Masato Horikawa, Yukio Kato, Yuichi Sugiyama, Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharmaceutical Research. ,vol. 19, pp. 1345- 1353 ,(2002) , 10.1023/A:1020358910490
Andre Van Kuilenburg, Rutger Meinsma, Lida Zoetekouw, Albert Van Gennip, High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity Pharmacogenetics. ,vol. 12, pp. 555- 558 ,(2002) , 10.1097/00008571-200210000-00007
C G Leichman, H J Lenz, L Leichman, K Danenberg, J Baranda, S Groshen, W Boswell, R Metzger, M Tan, P V Danenberg, Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. Journal of Clinical Oncology. ,vol. 15, pp. 3223- 3229 ,(1997) , 10.1200/JCO.1997.15.10.3223
Arne Zibat, Elisabeth Hustert, Oliver Burk, Michel Eichelbaum, Regina Eiselt, Ilka Brehm, Christine Fuss, Romy Mueller, Ulrich Brinkmann, Elena Presecan-Siedel, Leszek Wojnowski, Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metabolism and Disposition. ,vol. 29, pp. 1454- 1459 ,(2001)
P G Johnston, E R Fisher, H E Rockette, B Fisher, N Wolmark, J C Drake, B A Chabner, C J Allegra, The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Journal of Clinical Oncology. ,vol. 12, pp. 2640- 2647 ,(1994) , 10.1200/JCO.1994.12.12.2640
Giovanna Chimini, Michael Dean, Yannick Hamon, The human ATP-binding cassette (ABC) transporter superfamily Journal of Lipid Research. ,vol. 42, pp. 1007- 1017 ,(2001) , 10.1016/S0022-2275(20)31588-1
Sharon Marsh, Pui Kwok, Howard L McLeod, None, SNP databases and pharmacogenetics: great start, but a long way to go Human Mutation. ,vol. 20, pp. 174- 179 ,(2002) , 10.1002/HUMU.10115
Masato Horikawa, Yukio Kato, Charles A. Tyson, Yuichi Sugiyama, The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents: Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan Metabolites Drug Metabolism and Pharmacokinetics. ,vol. 17, pp. 23- 33 ,(2002) , 10.2133/DMPK.17.23
Howard L. McLeod, Cristi R. King, Sharon Marsh, Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clinical Colorectal Cancer. ,vol. 4, ,(2004) , 10.3816/CCC.2004.S.007
Howard L McLeod, Sharon Marsh, Pharmacogenetics goes 3D. Nature Genetics. ,vol. 37, pp. 794- 795 ,(2005) , 10.1038/NG0805-794